Corosolic acid induces cell cycle arrest and cell apoptosis in human retinoblastoma Y-79 cells via disruption of MELK-FoxM1 signaling

KE WANG1, XUE ZHU1, YONG YAO2, MIN YANG1, FANFAN ZHOU3 and LING ZHU4

1Key Laboratory of Nuclear Medicine, Ministry of Health, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi, Jiangsu 214063; 2Department of Ophthalmology, Wuxi People’s Hospital Affiliated to Nanjing Medical University, Wuxi, Jiangsu 214023, P.R. China; 3Faculty of Pharmacy, and 4Save Sight Institute, University of Sydney, Sydney, NSW 2000, Australia

Received November 27, 2017; Accepted March 23, 2018

DOI: 10.3892/or.2018.6339

Abstract. Retinoblastoma (Rb) is the most frequent primary intraocular tumor usually diagnosed in infants and children, and current therapy for such disease is still limited. Corosolic acid (CA), an ursane-type pentacyclic triterpene, has been assessed as a promising anticancer agent with little impact on untransformed cells. In the present study, we investigated the cytotoxic effect and underlying mechanism of CA on human retinoblastoma Y-79 cells. The viability of cells was verified by MTT assay. Cell cycle and apoptosis were evaluated by flow cytometric analysis. The expressions and activities of the related molecules were assessed by western blot analysis and luciferase assay. The results demonstrated that the treatment of CA dose-dependently induced cytotoxicity, cell cycle arrest and cell apoptosis in Y-79 cells. Furthermore, MELK-FoxM1 signaling was estimated to be involved in the cytotoxic effect of CA on Y-79 cells, and CA exerted its activity mainly through inhibition of the expression levels of MELK and FoxM1 as well as through suppression of the transcriptional activity of FoxM1 driven by itself or MELK. Our findings establish MELK-FoxM1 signaling as a promising therapeutic target for human retinoblastoma, and suggest the potential development of CA and its derivatives as novel drug candidates against this disease.

Introduction

Retinoblastoma is the most common primary intraocular tumor in infants and children, affecting ~1:14,000-1:22,000 live births (1-3). It is confirmed to be initiated by a bi-allelic inactivation of the retinoblastoma Rb1 gene in retinal cells in both the hereditary and sporadic types (4). Lack of a functional pRb1 induces defective differentiation and uncontrolled proliferation of a subset of human retinal cells, which then develop into tumors (5). Current therapy for retinoblastoma include local control of small to intermediate size tumors with laser combined with radiation and/or chemotherapy, or enucleation combined with or without systemic chemotherapy (6,7). Despite the progress in the treatment of retinoblastoma, significant issues remain unsolved. Enucleation of the eye leads to loss of vision and facial deformity (8), and radiotherapy and traditional chemotherapy increase the risk for the development of secondary tumors, such as osteosarcoma and melanoma (9,10). Therefore, the development of novel and effective molecular-targeted chemotherapeutic agents is needed for retinoblastoma treatment.

Ursane-type pentacyclic triterpenes, abundantly found in the plant kingdom, have been proposed to be a class of promising agents for cancer therapy (11). Of these compounds, ursolic acid (UA) is a prevalent pentacyclic triterpenoid and exhibits remarkable cytotoxic activity in various types of cancer cells (12-14). Such a compound exerts anticancer activity via induction of cell cycle arrest and cell apoptosis as well as inhibition of cell migration (15,16). Corosolic acid (CA) (Fig. 1A) is one analog of UA (Fig. 1A) and shows higher cytotoxic activity compared to UA in some types of cancer cells; however, the regulatory effect and underlying mechanism of CA on retinoblastoma is unexplored (17). In the present study, experiments were first designed to evaluate the cytotoxic effect of CA on Y-79 cells, an in vitro model of human retinoblastoma.

FoxM1, also known as FKHL16, MPP2 or TRIDENT, is a member of the Forkhead superfamily of transcription factors and plays a key role in the regulation of a variety of essential biological processes (18). Existing evidence has confirmed that FoxM1 closely participates in human cancers through inducing...
cancer initiation and promoting cancer progression (19). A recent study has revealed that the transcriptional activity of FoxM1 is regulated by maternal embryonic leucine-zipper kinase (MELK), a serine/threonine kinase (20). Joshi et al (21) demonstrated that MELK and FoxM1 are highly co-expressed, co-regulated and functionally related in glioblastoma multiforme (GBM), and that MELK is involved in the regulatory effect of FoxM1 on cancer cell survival. However, the role of MELK-FoxM1 signaling in retinoblastoma has never been investigated. A previous study by Wang et al (22) has confirmed that FoxM1 is a direct target of UA in MCF-7 human breast cancer cells. Due to the similar structure, the involvement of MELK-FoxM1 signaling in the effect of CA on Y-79 cells is further investigated.

Materials and methods

Chemicals and reagents. Corosolic acid (analytical standard, 89067) was purchased from Sigma-Aldrich (Merck KGaA, Darmstadt, Germany) and dissolved in dimethyl sulfoxide (DMSO). RPMI-1640 medium, DMEM/F12 medium, fetal bovine serum (FBS) and penicillin-streptomycin solution were obtained from Gibco (Grand Island, NY, USA). DMSO, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), propidium iodide (PI) and glutamine were obtained from Sigma-Aldrich (Merck KGaA, Darmstadt, Germany). Lipofectamine 2000 was obtained from Invitrogen (Carlsbad, CA, USA). The kit for apoptosis was obtained from BD Biosciences (San Jose, CA, USA). The antibodies used in the present study were as follows: p53 (cat. no. 48818; Cell Signaling Technology, Inc., Danvers, MA, USA), p21 (cat. no. ab109520; Abcam, Cambridge, MA, USA), cyclin B1 (cat. no. 4135; Cell Signaling Technology, Inc., Danvers, MA, USA), Cdc25B (cat. no. ab124819; Abcam), Bax (cat. no. 2774; Cell Signaling Technology, Inc.), Bcl-2 (cat. no. 15071; Cell Signaling Technology, Inc.), caspase-9 (cat. no. ab32539; Abcam), caspase-3 (cat. no. 9662), ASK1 (cat. no. 3762), p-JNK (cat. no. 9255), JNK (cat. no. 9252), p-p38 (cat. no. 9216), p38 (cat. no. 9212), FoxM1 (cat. no. 5436), MELK (cat. no. 2274), β-actin (cat. no. 4970) and SP/PS (cat. no. ab32539; Abcam), caspase-9, caspase-3 (cat. no. 9216), FoxM1 (cat. no. 5436), MELK (cat. no. 2274), β-actin (cat. no. 4970); all were from Cell Signaling Technology, Inc.) and the HRP conjugated goat anti-mouse (sc-2031) rabbit (sc-2030) secondary antibodies (Santa Cruz Biotechnology, Inc., Dallas, TX, USA). All other chemicals and reagents were purchased from Beyotime Institute of Biotechnology (Nantong, China).

Cell culture and transfection. The human retinoblastoma cell line Y-79 and the human RPE cell line ARPE-19 were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). Y-79 cells were cultured in RPMI-1640 medium with 10% FBS and 1% penicillin-streptomycin (PS). ARPE-19 cells were cultured in DMEM/F12 medium with 10% FBS, 2 mM glutamine and 1% PS. Cells were maintained at 37°C in a humidified atmosphere containing 5% CO2 and passaged once every 3 days. For the analysis of function of MELK-FoxM1 signaling, cells were transiently transfected with the indicated plasmids (FoxM1-luc reporter vector (2 µg, provided by Dr Fanfan Zhou's Laboratory, University of Sydney), FoxM1 expression vector (2 µg, pCW57.1-FOXM1b plasmid; cat. no. 68811; Addgene, Cambridge, MA, USA) or MELK expression vector (2 µg, provided by Dr Fanfan Zhou's Laboratory, University of Sydney)) or small interfering RNA for MELK (100 pmol MELK siRNA; cat. no. sc-61016; Santa Cruz Biotechnology, Inc.) using Lipofectamine 2000. Cells were cultured for 24 h post transfection and the expressions of the related molecules were assessed by western blot analysis before treatment with the indicated agents.

Measurement of cell viability. To assess the effect of CA on cell viability, MTT assay was used as previously mentioned (23). After treatment, 10 µl of MTT (5 mg/ml stock in PBS) was added per well and the incubation was continued for 2 h. Then, the culture medium was removed and 100 µl DMSO was added to dissolve the formazan crystals. The absorbance at 570 nm was determined with an ELISA reader (Bio-Rad Laboratories, Hercules, CA, USA).

Measurement of cell cycle distribution. To assess the effect of CA on cell cycle distribution, PI staining was used as previously mentioned (24). After treatment, cells were collected by centrifugation, fixed in 70% ethanol, re-suspended in PBS containing RNase (1 mg/ml) and PI (50 µg/ml), incubated for 30 min in the dark and then analyzed using flow cytometry (Becton-Dickinson; BD Biosciences).

Measurement of cell apoptosis. To assess the effect of CA on cell apoptosis, double staining with Annexin V-FITC and PI was used as previously described (24). After treatment, cells were collected by centrifugation, washed twice with cold PBS, re-suspended in binding buffer containing 10 µl of Annexin V-FITC stock and 10 µl of PI, and then analyzed using flow cytometry (Becton-Dickinson; BD Biosciences).

Western blot analysis. To assess the effect of CA on the expression profiles of related proteins, western blot analysis was used as previously described (25). After treatment, cells were lysed for 20 min in lysis buffer and the concentration of protein sample was determined with the Bradford method. Samples (50 µg) were separated on SDS-PAGE gel (10%) and electro-transferred onto polyvinylidene fluoride (PVDF) membrane. After blocking, the membrane was incubated with the primary antibody at 4°C for overnight and horseradish peroxidase (HRP)-conjugated secondary antibody at 37°C for 2 h. The protein bands were visualized by ECL detection kit (Beyotime Institute of Biotechnology).

Luciferase assay. To assess the effect of CA on the transcriptional activity of FoxM1, luciferase assay was used as previously described (26). After transfection, cells were treated with the indicated agents for 24 h and the luciferase activity was measured using luciferase assay system. Relative luciferase activity was expressed as percentage induction of promoter activity by the FoxM1 expression vector, where the promoter activity resulting from transfection with FoxM1 was set at 100%.

Statistical analysis. Biostatistical analyses were conducted with Prism 5.0 (GraphPad Software, Inc., La Jolla, CA, USA) and SPSS 16.0 software package (SPSS, Inc., Chicago, IL, USA). All experiments were conducted in triplicate and the
Results

Cytotoxic effect of CA on cell proliferation in human retinoblastoma Y-79 cells. In order to analyze the biological effect of CA, human retinoblastoma Y-79 cells were treated with various concentrations of CA for 24 or 48 h and cell viability was assessed by MTT assay. The results demonstrated that CA significantly inhibited cell proliferation of Y-79 cells in a dose- and time-dependent manner (Fig. 1B). The value of IC50 was calculated using the GraphPad Prism software. The results indicated that treatment of 4.15 µM CA for 24 h or 3.37 µM for 48 h resulted in a reduced cell proliferation by 50% in the Y-79 cells. However, CA treatment had little impact on untransformed cells such as the human retinal pigment epithelial cell line ARPE-19 (Fig. 1C). Then, treatment with concentrations of 2, 5 and 10 µM CA for 24 h was selected to continue this study. The data suggest that CA has an inhibitory effect against human retinoblastoma Y-79 cells.

Promotive effect of CA on cell cycle arrest in human retinoblastoma Y-79 cells. In order to identify whether CA induces proliferation inhibition via triggering cell cycle arrest, human retinoblastoma Y-79 cells were treated with CA (0, 2, 5 and 10 µM) for 24 h, and cell cycle distribution was assessed by flow cytometric analysis. The results indicated that CA treatment (10 µM) significantly increased the population of cells in the G2/M phase to 32.14±1.37 compared to the non-treatment cells (12.53±1.18) (Fig. 2). Furthermore, the change in cell cycle regulators upon CA treatment was analyzed using western blot analysis. As shown in Fig. 3, CA treatment dose-dependently affected the cell phase distribution via inducing upregulation of p53 and p21WAF1 as well as downregulation of cyclin B1, Cdc25B and Aurora B in the Y-79 cells.

Promotive effect of CA on cell apoptosis in human retinoblastoma Y-79 cells. In order to identify whether CA induces proliferation inhibition via triggering cell apoptosis, human retinoblastoma Y-79 cells were treated with CA (0, 2, 5 and 10 µM) for 24 h, and cell apoptosis was assessed by flow cytometric analysis. The results indicated that CA treatment (10 µM) significantly increased the percentage of apoptotic cells to 54.58±4.46 compared to the non-treatment cells (1.18±0.25%) (Fig. 4). Furthermore, the change in cell apoptosis-related signaling pathways upon CA treatment was analyzed. First, as shown in Fig. 5A, CA treatment dose-dependently affected the mitochondrial pathway via inducing upregulation of Bax, downregulation of Bcl-2 and cleavage of caspase-9 and caspase-3. Then, as shown in Fig. 5B,
CA treatment dose-dependently affected the MAPK pathway via inducing upregulation of ASK1 and phosphorylation of JNK and p38, but not ERK (data not shown).

**Inhibitory effect of CA on MELK-FoxM1 signaling in human retinoblastoma Y-79 cells.** A previous study estimated that FoxM1 is the direct target of UA (22). First, we examined the inhibitory effect of CA on the expression profiles of MELK and FoxM1. The results revealed that CA treatment for 24 h significantly suppressed the expression levels of MELK and FoxM1 in a dose-dependent manner in Y-79 cells (Fig. 6A). In addition, MELK overexpression did not affect the inhibitory effect of CA on FoxM1 expression; likewise FoxM1 overexpression did not affect the inhibitory effect of CA on MELK expression (Fig. 6B). Then, we examined the inhibitory effect of CA on the transcriptional activity of FoxM1. As shown in Fig. 7, CA treatment for 24 h significantly suppressed the transcriptional activity of FoxM1 in cells transfected with FoxM1 + MELK (-) or FoxM1 in a dose-dependent manner, indicating that CA abrogated FoxM1 activity driven by FoxM1 itself or MELK, and such a compound abrogated MELK-dependent FoxM1 activity possibly by inhibiting MELK expression.

**MELK-FoxM1 signaling is involved in the inductive effect of CA on cell cycle arrest and cell apoptosis in human retinoblastoma Y-79 cells.** Several lines of evidence have suggested that MELK-FoxM1 signaling plays a key role in the process of cell cycle and cell apoptosis (27-29). To examine whether CA induces cell cycle arrest and cell apoptosis via regulating
MELK-FoxM1 signaling, Y-79 cells were transfected with FoxM1 alone, MELK alone or MELK + FoxM1, and then treated with CA (10 µM) for 24 h. The results indicated that overexpression of MELK + FoxM1, rather than FoxM1 alone, significantly reversed the inductive effect of CA on cell cycle arrest and cell apoptosis (Figs. 8A and 9A). However, overexpression of MELK alone slightly attenuated the inductive effect of CA compared to the other groups, indicating that MELK
Corosolic acid (CA) has been assessed as a promising anti-cancer agent, and existing evidence has estimated that CA can affect a wide variety of human cancers, such as hepatocellular (30), colorectal (31) and gastric carcinoma (32). It has been reported that CA inhibits cell growth with lower IC50 values in some types of cancer cells when compared to these values for UA (17). To date, the effect of CA on human retinoblastoma cancer cells has never been explored. In the present study, we revealed that CA treatment significantly inhibited cell growth by inducing cell cycle arrest and cell apoptosis in Y-79 cells, an in vitro model of human retinoblastoma. As an analog of UA, CA markedly changed the expression profiles of FoxM1 and its downstream effectors, which include cell cycle regulators such as p53, p21, cyclin B1, Cdc25B and Aurora B as well as cell apoptosis regulators from the mitochondrial and MAPK pathways. However, the precise mechanism attributed to the cytotoxic effect of CA on Y-79 cells remained inconclusive.

FoxM1 plays a critical role in the regulation of various biological processes (33) In vitro, loss of FoxM1 results in cell cycle arrest and subsequent defective mitotic spindle integrity; in vivo, loss of FoxM1 leads to embryonic lethality due to a failure to enter mitosis (34). Existing evidence has shown that FoxM1 deregulation is associated with cancer progression and cancer drug resistance (35). Aytes et al (36) demonstrated the FoxM1 target gene CENPF can synergistically interact with FoxM1 to
drive prostate cancer malignancy. Nestal de Moraes et al (37) showed that FoxM1 upregulates anti-apoptotic genes XIAP and survivin by interacting with their promoters, contributing to the chemoresistance of breast cancer. Therefore, FoxM1 has become an attractive therapeutic target in the fight against several lines of cancers. Existing evidence has confirmed that FoxM1 is a direct target of UA. In MCF-7 cancer cells, UA treatment inhibits the expression level of FoxM1, and FoxM1 inhibition by UA suppressed cell proliferation and induced cell cycle arrest (22). In the present study, treatment of CA, an analog of UA, significantly suppressed the expression level and the transcriptional activity of FoxM1; however, transfection of FoxM1 partially attenuated the cytotoxic effect of CA on Y-79 cells, indicating that FoxM1 was not the only target of this compound. MELK is a member of the AMPK/Snf1 family, and elevated MELK expression is observed in various types of human cancer and is correlated with the poor prognosis of cancer patients (20,38). Wang et al (27) revealed that MELK is required for the transforming activity, survival and proliferation of basal-like breast cancer cells. Our results indicated that treatment of CA also significantly suppressed the expression level of MELK. However, transfection of MELK slightly attenuated the cytotoxic effect of CA on Y-79 cells, indicating that CA may exert its activity via inhibition of MELK combined with other related factors, rather than MELK alone. Joshi et al (21) reported that FoxM1 is a key substrate of MELK and MELK is essential for the phosphorylation and activation of FoxM1, which then results in a subsequent change in cell cycle and cell apoptosis regulatory genes. Xia et al (39) reported that MELK regulates cell cycle progression and mitosis-related genes mainly through activation of FoxM1. In the present study, we initially found that treatment of CA suppressed the expression levels of both MELK and FoxM1; however, there was no interaction between MELK expression and FoxM1 expression. We then found that treatment of CA suppressed the transcriptional activity of FoxM1 to the similar baseline level in cells transfected with FoxM1 + MELK(-) and in cells transfected with FoxM1 alone, which implied that
CA abrogated FoxM1 activation driven by itself or MELK. Moreover, CA abrogated MELK-driven FoxM1 activity possibly by inhibiting MELK expression. Further study showed that transfection of both MELK and FoxM1, rather than FoxM1 alone, significantly attenuated the effect of CA. In addition, MELK transfection alone slightly attenuated the effect of CA on the cell cycle, cell apoptosis and the related mediators compared to FoxM1 transfection alone, indicating that MELK may exert its effect mainly via activating FoxM1. Collectively, we propose that CA exhibits cytotoxic effects on cell proliferation and a promotive effect on cell cycle arrest and cell apoptosis by inhibiting the expression levels of MELK and FoxM1 as well as suppressing the transcriptional activity of FoxM1 driven by itself or MELK.
In summary, the present study revealed that MELK-FoxM1 signaling is a potential therapeutic target for human retinoblastoma, and provides novel insight into the potential application of corosolic acid and its derivatives in the treatment of this disease.

Acknowledgements

The authors thank Dr Fanfan Zhou for her technical support.

Funding

The present study was supported by grants from the National Significant New Drugs Creation Program (no. 2017ZX09304021), the Jiangsu Provincial Medical Innovation Team (no. CXTDA2017024), the Major Project of Wuxi Municipal Health Bureau (nos. ZS201401 and Z201508) and the Project of Wuxi Municipal Science and Technology Bureau (nos. CSE31N1520 and CSE31N1621).

Availability of data and materials

The datasets used during the present study are available from the corresponding author upon reasonable request.

Authors' contributions

KW, YY and MY contributed to the design of the study and wrote the manuscript. KW and XZ performed the experiments. FFZ analyzed the data. LZ performed the analysis with constructive discussions. All authors read and approved the manuscript and agree to be accountable for all aspects of the research in ensuring that the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References


